Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 53Lymphoma, Mantle-Cell 34Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Follicular 18Lymphoma 15Lymphoma, Non-Hodgkin 13Waldenstrom Macroglobulinemia 12Lymphoma, B-Cell 12Recurrence 9Lymphoma, B-Cell, Marginal Zone 9Leukemia 6Bronchiolitis Obliterans Syndrome 6Multiple Myeloma 5Leukemia, Lymphoid 5Leukemia, B-Cell 5Hodgkin Disease 5Hematologic Neoplasms 4Burkitt Lymphoma 4Neoplasms 3Graft vs Host Disease 3Lung Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Chromosome 17 deletion 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × ibrutinib × Clear all
NCT03525925 2024-03-18

Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡